Research & Development: Page 7
-
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
By Amy Baxter • Oct. 31, 2024 -
Getty Images via Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Photo illustration: Industry Dive; Getty Images via Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
By Michael Gibney • Oct. 30, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
eranicle via Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Stock via Getty Images
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
By Kelly Bilodeau • Oct. 28, 2024 -
Permission granted by Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
By Michael Gibney • Oct. 23, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
Metamorworks/ICON
Sponsored by ICONHow AI can manage the risks and costs of postmarketing requirements
PMRs are not new but drug developers can use AI to predict risk and manage costs earlier in studies.
By Alexandre Malouvier • Oct. 21, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
Christoph Burgstedt via Getty Images
Wave sees RNA editing validation in early trial results
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
By Ben Fidler , Ned Pagliarulo • Oct. 17, 2024 -
iStock via Getty Images
As new Alzheimer’s biomarkers come into play, here’s where the money is going
The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.
By Michael Gibney • Oct. 17, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.
By Meagan Parrish • Oct. 16, 2024 -
Scott Olson via Getty Images
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
By Jonathan Gardner • Oct. 15, 2024 -
Dan Kitwood/Getty Images via Getty Images
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
By Michael Gibney • Oct. 15, 2024 -
Stock via Getty Images
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Motortion via Getty Images
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
Stock via Getty Images
As AI transforms drug development, biotechs might not need as much Big Pharma support
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
By Amy Baxter • Oct. 9, 2024 -
Scott Olson via Getty Images
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
By Kelly Bilodeau • Oct. 7, 2024 -
Stock via Getty Images
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
By Meagan Parrish • Oct. 4, 2024 -
iStock via Getty Images
How Roche plans to fill a projected $8B sales gap
Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.
By Amy Baxter • Oct. 2, 2024 -
Honglouwawa via Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 2, 2024 -
Permission granted by Biocom
Q&ACalifornia is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Stock via Getty Images
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
By Kelly Bilodeau • Sept. 30, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024
Previous
